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ABSTRACT 
 
Enzyme-inducing antiepileptic drugs (AEDs) produce many alterations in metabolism, including 
vitamin levels. Whether they produce clinically-relevant deficiency of B vitamins has rarely been 
assessed. We obtained B vitamin levels in patients who were being converted from an inducing 
AED (phenytoin or carbamazepine) to a non-inducing AED (levetiracetam, lamotrigine, or 
topiramate), with measurements both before and ≥ 6 weeks after the switch. A group of normal 
subjects underwent the same studies. Neither folate nor B12 deficiency was seen in any patient. 
Vitamin B6 deficiency was found in 16/33 patients (48%) taking inducers, compared to 1/11 
controls (9%; p=0.031). After switch to non-inducers, only 7 patients (21%) were B6 deficient 
(p=0.027). The incidence of deficiency was similar regardless of which inducing or non-inducing 
AED was being taken. Our findings demonstrate that treatment with inducing AEDs commonly 
causes pyridoxine deficiency, often severe. This could conceivably contribute to the 
polyneuropathy sometimes attributed to older AEDs, as well as other chronic heath difficulties. 
  
INTRODUCTION 
 Enzyme-inducing antiepileptic drugs (AEDs) produce a considerable number of 
metabolic alterations, including changes in serum lipids, hormones, bone turnover, and various 
vitamin levels [1]. Some of these parameters, such as cholesterol, are appropriately examined in 
a continuous fashion, as their contribution to disease is graded. In contrast, other measures are 
best examined in a dichotomous fashion, as their contribution to clinical disease is generally felt 
to depend upon whether a patient’s level declines below a certain critical threshold. 
 The B vitamins folate, cyanocobalamin (B12), and pyridoxine (B6) belong to the latter 
category. A number of studies have examined the effects of enzyme-inducing and other AEDs on 
these vitamins, but most have looked at them as continuous variables [2-4]. This approach is less 
than ideal for determining clinical relevance in some respects, as a patient whose vitamin level 
declines a bit due to AED therapy will suffer no clinical consequences as long as that level 
remains in the range that will appropriately support normal function. Whether AEDs produce 
frank deficiency of vitamins has been little-studied. B6 deficiency in epilepsy patients has been 
the subject of only a single uncontrolled study[5]. One large study did examine folate and B12 
levels in a dichotomous fashion, finding that deficiency of one or both these vitamins was more 
common in patients taking a number of AEDs, including many inducers (phenytoin, 
carbamazepine, primidone), some newer drugs with limited enzyme-inducing capacity 
(oxcarbazepine, topiramate) and several non-inducers (gabapentin, pregabalin, valproate) [6]. 
This study was limited by its cross-sectional design, reducing its ability to attribute these 
deficiencies to the effects of drugs. These authors did not examine B6 levels. 
 The present study assessed B vitamin deficiency in a group of patients transitioning from 
an older, enzyme-inducing AED to a newer generation AED. The crossover design, together with 
a normal control group, permits attribution of drug effects. Our goal was to determine whether 
inducing AEDs produce clinically relevant deficiency of B vitamin levels. 
 
 
 
  
METHODS 
 We studied patients with epilepsy on CBZ or PHT monotherapy whose treatment 
regimen was being changed to monotherapy with one of the newer agents LEV, LTG, or TPM. 
Patients were participating in one of two studies designed to examine the effects of AED 
conversion on lipids and other vascular risk factors [7, 8]. Any patient undergoing such a drug 
switch was asked to participate. Patients had been taking the former drugs for at least one month, 
and the decision to alter therapy was made by the patient’s treating physician for clinical reasons 
(e.g., side effects, inadequate seizure control, or concerns about chronic AED use). These 
patients were compared to the same group of normal subjects utilized in our previous 
investigation[7]. The drug-treated patients provided a fasting blood sample during therapy with 
the initial drug, and a second sample following AED conversion, at least 6 weeks after the 
inducing agent had been discontinued. Target doses of AEDs were generally low: 500 mg BID of 
LEV, 100 - 200 mg BID of LTG, and 50-75 mg BID of TPM (except for a single patient taking 
TPM at 150 mg BID).  In the normal subjects, two fasting blood samples were taken 10 weeks 
apart (comparable to the the anticipated inter-sample time in the drug-treated patients, whose 
inducer would be gradually tapered over several weeks).  
 Blood samples were analyzed for folate, pyridoxal-5’-phosphate (B6), and B12 levels in 
serum, as well as the level of the AED the patient was taking at the time. We excluded from the 
present analyses any patients with conditions which might be expected to have a major impact 
upon nutrient absorption, such as pernicious anemia, celiac disease, active inflammatory bowel 
disease, or prior bariatric surgery. In addition, we excluded patients who had a major change in 
health state during the study period (e.g. pregnancy) which might be expected to alter vitamin 
levels over the course of the study. Subjects taking high-dose B vitamin supplements were also 
excluded. Those taking multivitamins were found to have B6 levels which were markedly higher 
than all other subjects at baseline, and as a consequence were excluded from B6 analyses. Folate 
and B12 levels in these latter patients at baseline did not differ from those of the other subjects. 
Some individual measurements were not carried out in certain samples due to laboratory or 
handling errors. The total number of patients was n=28 for folate, n=29 for B12, and n=33 for 
B6; for normal subjects n=14 for folate and B12 and n=11 for B6. Vitamin levels were 
  
performed by Quest Diagnostics (San Juan Capistrano, CA). Folate and B12 were measured 
using chemiluminescent immunoassay with a total allowable error of 30% and coefficients of 
variation of 6.0-8.3% and 3.3-9.0% respectively. B6 was measured in normal subjects and in the 
majority of the patients using a radioenzyme assay method with a coefficient of variation of 
13.3-14.4% and lower limit of quantitation of 2.5 ng/mL. The laboratory subsequently updated 
its technique for this measure, such that in the remainder of the patients B6 was measured using 
liquid chromatography and tandem mass spectometry with a lower quantitation limit of 2.0 
ng/mL and a total allowable error of 25%. The correlation between the two B6 detection methods 
is >97%.  Comparison of B vitamin deficiency in drug-treated and normal subjects was 
performed using the Fisher’s Exact or Chi-squared tests. The incidence of B6 deficiency in drug-
treated patients before and after drug switch was analyzed using the McNemar test. Analyses 
were performed using InStat 3.0 (GraphPad, San Diego, CA).  
 
 
RESULTS 
 
The epilepsy patients averaged 44 years of age (range 18-88) and were 57% female. With 
regard to ethnicity, the group was approximately 77% Caucasian, 13% of African descent, 7% 
Latino, and 3% from other ethnic groups. They had been treated with their initial medication for 
anywhere between 30 days and 35 years. Those taking CBZ had serum levels ranging from 1.9- 
16.6 µg /mL (mean: 8.7), with all but one patient having a level > 4.0. Among those taking PHT, 
levels ranged from 3.3 - 28.9 µg /mL (mean: 15.1); two patients had levels of 3.3 and 5.1, with 
all the rest having levels ≥8.9. The total time between the two blood draws ranged from 42 to 
308 days (mean: 123). The normal subjects not taking AEDs who served as comparators were 
described in a previous publication[7]. This group was similar in age, gender, and race to the 
patient cohort. 
 Using a threshold value of <3 ng/ml, folate deficiency was not seen in any of the patients 
during treatment with the older AEDs, nor when they were switched to the newer AEDs. A 
  
single PHT-treated patient had a folate level right at the cutoff (3 ng/ml), and this increased to 
3.5 ng/ml after  switch to a newer AED. Thus, while folate levels were lower during inducer 
treatment (data not shown), this did not produce threshold deficiency. None of the normal 
subjects were folate deficient at either blood draw. 
 With regard to B12 deficiency, using the standard cutoff value of <200 pg/ml, there was 
no B12 deficiency seen among any of the epilepsy patients, either under treatment with an 
inducing AED or under treatment with a non-inducing drug. In fact, there was more B12 
deficiency among the normal subjects: none were deficient at the first draw, though several were 
close to the cutoff, and 3 actually declined into the deficient range at the time of the second draw. 
Thus, we found no evidence of clinically-relevant B12 deficiency among AED-treated epilepsy 
patients. 
 Results with respect to B6 deficiency are shown in Figure 1. Using the standard cutoff of 
5 ng/ml, 16 of 33 epilepsy patients (48%) were B6 deficient, as compared to 1/11 normal 
subjects (9%). B6 deficiency was significantly more common at baseline in the inducer-treated 
patients than in the normal subjects (Fisher’s Exact, p=0.031). The degree of B6 deficiency was 
not trivial, with 10 of these 16 patients, or 30% of the entire cohort, having levels at or below the 
limit of detection of the predominant assay (≤2.5 ng/ml). In fact, using that number as a stringent 
cutoff, B6 deficiency remained more common in patients than in controls (Fisher’s Exact, p= 
0.046). Using the more lenient threshold of <7.5 ng/ml, the high prevalence of deficiency 
remained a trend (Fisher’s Exact, p = 0.096). Following switch to a non-inducing AED, B6 
deficiency was seen in 7 of 33 epilepsy patients (21%), a significant decline from the 48% 
incidence in those same patients during inducing-drug treatment (McNemar, p=0.027) (Fig.1). 
 The findings do not appear meaningfully related to the specific assay used, as B6 
deficiency was seen in 12/27 patients (44%) using the radioenzyme assay and in 4/6 patients 
(66%) using the newer mass spectrometry assay.  The findings also do not appear related to the 
specific inducing or non-inducing AED used, as B6 deficiency was seen in 7 of 12 patients while 
taking PHT (58%) and in 9 of 21 patients taking CBZ (43%). When PHT- and CBZ-treated 
patients were considered as separate groups and compared to normal subjects, the incidence of 
B6 deficiency remained significant (Chi-squared, p=0.046). Once crossed-over to a non-inducing 
  
AED, B6 deficiency appeared in nearly-identical proportions regardless of whether the patient 
was switched to LEV, LTG, or TPM (Figure 2). 
 
  
 
DISCUSSION 
 
 A number of studies have examined B vitamin levels in AED-treated epilepsy patients, 
generally in the context of their potential contribution to homocysteine levels. As a consequence, 
the majority of these studies have been concerned with the magnitude and statistical significance 
of any serum level changes, since changes throughout the range of values may impact upon 
homocysteine levels. Yet for most other clinical concerns, changes in vitamin levels within the 
normal range are unlikely to be clinically relevant. For this reason, we undertook to specifically 
examine the issue of whether treatment with enzyme-inducing AEDs contributes to threshold 
deficiency of B vitamins. 
 The major result of the present investigation was the finding that B6 deficiency is very 
common in the inducer-treated population, and in most cases was improved by switch to a non-
inducer. Several studies have found reduced B6 levels in CBZ-treated patients, and in two of the 
studies this could clearly be attributed to CBZ [2, 4, 9]. However, none of these studies reported 
the incidence of B6 deficiency, so that the clinical relevance of these changes, other than their 
potential contribution to homocysteine deficiency, remained uncertain. Only one previous study 
examined B6 deficiency in a categorical fashion, finding as we did that the majority of PHT- and 
CBZ- treated patients were B6 deficient; however, this study did not include a control group[5]. 
Thus, to our knowledge, ours is the first study to demonstrate that frank B6 deficiency is more 
common in CBZ- and PHT-treated patients with epilepsy than in control subjects, and that this 
deficiency is very likely caused or exacerbated by the drugs themselves. 
 Furthermore, the degree of B6 deficiency in these patients was remarkable, with 30% of 
the entire inducer-treated cohort having B6 levels that were undetectable or nearly so. Relatively 
little is known about the consequences of B6 deficiency, as it is distinctly uncommon in adults. 
Among the most well-established clinical consequences of B6 deficiency is peripheral 
neuropathy, generally encountered in the context of treatment with the antitubercular drug 
isoniazid, which forms a complex with B6 and thus reduces its availability to tissues[10]. It is 
standard clinical practice to supplement isoniazid-treated patients with B6 to avoid the depletion 
  
that can otherwise occur via this mechanism. This neuropathic action of isoniazid, and the 
present findings, are of interest in light of the evidence  that PHT may be neuropathic[11, 12] . 
There is also evidence that other inducing AEDs may contribute to the development of peripheral 
neuropathy [13, 14]. Further clinical investigation is warranted to assess the possibility that this 
could be due to B6 deficiency. Deficiency of B6 may also contribute to anemia and may increase 
the risk of a number of cancers[15]. In addition, there is the well-documented genetic condition 
of B6-dependent epilepsy in infants[16]. It is not clear that B6 deficiency contributes to seizures 
in adults or older children lacking the relevant mutation, though a recent case series suggested 
B6 deficiency as a cause of new-onset refractory seizures in several critically ill patients[17]. 
Specific study would be required to determine whether the kind of extreme B6 deficiency seen 
here might contribute to chronic AED-resistant epilepsy. 
 The mechanism for B6 deficiency caused by inducing AEDs remains unclear. B6 is 
oxidized in the liver prior to urinary excretion[15], and such oxidizing enzymes are frequent 
targets of enzyme inducers, so that it is likely that increased activity of the oxidizing enzyme in 
the presence of PHT or CBZ results in increased catabolism of B6. Another alternative is that, 
like isoniazid, these drugs form a complex with B6 and result in increased urinary excretion. We 
are not aware of any pharmacologic investigation of these hypotheses. 
 The noteworthy negative findings in our study involved the absence of folate or B12 
deficiency in the AED-treated epilepsy patients. The findings with regard to B12 are in good 
agreement with those of Linnebank et al [6], who found that B12 deficiency was uncommon in 
inducer-treated patients (or in patients taking any AED), and no more common than in healthy 
controls. Thus, while both those authors and our group [7]  found that inducers appear to lower 
B12 levels, it is unlikely that this effect is of clinical significance. With regard to folate, those 
authors found that about a quarter of CBZ- or PHT-treated patients were folate deficient, a 
finding which contrasts starkly with our data. Both studies used the same cutoff for folate 
deficiency, and only one of our patients in whom folate was measured was taking a multivitamin 
supplement. It is possible that differences in diet could explain the folate discrepancy, as folate 
supplementation of foodstuffs is common in the United States, but not in Germany. This points 
up a limitation of our study, and indeed of virtually all studies in this area: absence of knowledge 
  
regarding subjects’ nutritional intake. Dietary assessments are, in general, difficult and of 
dubious accuracy due to poor subject recall, inability to corroborate food intake, and other 
factors. This makes the use of our repeated measures design particularly valuable, as it is 
unlikely that subjects would have experienced major changes in diet that would have 
meaningfully affected vitamin levels during the period between the two blood draws; 
furthermore, any tendency to alter diet would have been reflected equally in both patient and 
control groups. Thus, even with this limitation, our study points to the effects of inducing AEDs 
as being causative of B6 deficiency. It is also worth noting the ability of folate supplementation 
to mask functional B12 deficiency, a phenomenon which has been specifically reported in the 
epilepsy population[18]. While this could conceivably have been a factor in our cohort, the 
results with respect to B12 were similar to those seen in the study done in Germany, where there 
is little folate supplementation of food. Thus, we feel this is unlikely to have been a meaningful 
contributor to our negative findings with respect to B12. 
 In summary, our data reveal a high prevalence and degree of B6 deficiency in patients 
under treatment with inducing AEDs. While we cannot exclude that some of this might relate to 
the underlying epilepsy, the design of our study makes it clear that PHT and CBZ are responsible 
for the lion’s share of this finding. Further work is also needed to ascertain the potential clinical 
impact of B6 deficiency in this population with regard to peripheral neuropathy, 
homocysteinemia, seizures, or other metabolic consequences. 
  
FIGURE LEGENDS 
 
 
 
Figure 1: Vitamin B6 deficiency during treatment with various AEDs 
 
Bars represent the fraction of patients deficient during the period of treatment with a given 
inducing AED (shown in green) or non-inducing AED (in blue). Patient numbers were n=12 for 
phenytoin (PHT), n=21 for carbamazepine (CBZ), n=9 for levetiracetam (LEV), n=13 for 
lamotrigine (LTG), and n= 11 for topiramate (TPM). 
 
 
 
 
 
 
Figure 2: Vitamin B6 deficiency in epilepsy patients and in normal subjects 
 
 
Green bars represent the fraction of patients deficient at baseline, while blue bars represent the 
fraction of patients deficient at the second draw.  *p<0.05 (Fisher’s Exact) for comparison of 
epilepsy patients vs. normal controls at baseline (draw 1).  †p<0.05 (McNemar) for comparison 
of epilepsy patients at baseline (while taking an inducing drug) and at draw 2 (after switch to 
newer-generation drug). 
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